Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Practice Guidelines
100%
Outpatient Setting
100%
American College of Physicians
100%
Migraine Headache
100%
Episodic Migraine
100%
Pharmacologic Treatment
100%
Beta-blockers
28%
Adverse Events
28%
Selective Serotonin Reuptake Inhibitors
28%
Migraine Frequency
28%
Physical Function
14%
Lisinopril
14%
Topiramate
14%
Monotherapy
14%
Patient Preference
14%
Migraine
14%
Lack of Response
14%
Comparative Effectiveness
14%
Quality of Life
14%
Initial Treatment
14%
Evaluation Approach
14%
U.S. Food
14%
Metoprolol
14%
Assessment Approach
14%
Propranolol
14%
Emergency Department Visits
14%
Rimegepant
14%
Development Approach
14%
Number of Days
14%
Physician Recommendation
14%
Amitriptyline
14%
Tricyclic Antidepressants
14%
Fluoxetine
14%
Venlafaxine
14%
Valproate
14%
Grading of Recommendations
14%
Acute Migraine Treatment
14%
Migraine Prevention
14%
Clinical Considerations
14%
Telmisartan
14%
Life Functioning
14%
Patient Values
14%
Candesartan
14%
Comparative Harms
14%
Non-pregnant Adults
14%
Migraine Patients
14%
Headache Days
14%
Medication Label
14%
Angiotensin-converting Enzyme Inhibitor (ACEi)
14%
Comparative Benefit
14%
Angiotensin
14%
Serotonin-norepinephrine Reuptake Inhibitors
14%
Galcanezumab
14%
Gepants
14%
Atogepant
14%
Fremanezumab
14%
Eptinezumab
14%
Erenumab
14%
Calcitonin Gene-related Peptide Monoclonal Antibody
14%
Assessment Development
14%
Antiseizure Medication
14%
Assessment Evaluation
14%
Economic Evidence
14%
Additional Context
14%
Calcitonin Gene-related Peptide Receptor Antagonist
14%
Migraine-related Disability
14%
Migraine Duration
14%
Medicine and Dentistry
Outpatient
100%
Clinical Guideline
100%
Migraine
100%
Episodic Migraine
100%
Clinician
50%
Adverse Event
33%
Quality of Life
16%
Monotherapy
16%
Systematic Review
16%
Emergency Department
16%
Lisinopril
16%
ACE Inhibitor
16%
Headache
16%
Calcitonin Gene Related Peptide
16%
Metoprolol
16%
Fluoxetine
16%
Venlafaxine
16%
Amitriptyline
16%
Selective Serotonin Reuptake Inhibitor
16%
Candesartan
16%
Tricyclic Antidepressant
16%
Telmisartan
16%
Calcitonin Gene-Related Peptide Receptor Antagonist
16%
Monoclonal Antibody
16%
Propranolol
16%
Angiotensin
16%
Sodium Valproate
16%
Serotonin-Norepinephrine Reuptake Inhibitor
16%
Topiramate
16%
Fremanezumab
16%
Eptinezumab
16%
Galcanezumab
16%
Rimegepant
16%
Atogepant
16%
Erenumab
16%
Pharmacology, Toxicology and Pharmaceutical Science
Episodic Migraine
100%
Migraine
100%
Adverse Event
33%
Sodium Valproate
16%
Tricyclic Antidepressant
16%
Serotonin-Norepinephrine Reuptake Inhibitor
16%
Propranolol
16%
Rimegepant
16%
Lisinopril
16%
Headache
16%
Dipeptidyl Carboxypeptidase Inhibitor
16%
Calcitonin Gene Related Peptide
16%
Metoprolol
16%
Selective Serotonin Reuptake Inhibitor
16%
Amitriptyline
16%
Fluoxetine
16%
Venlafaxine
16%
Candesartan
16%
Telmisartan
16%
Calcitonin Gene Related Peptide Receptor Antagonist
16%
Angiotensin
16%
Monoclonal Antibody
16%
Topiramate
16%
Monotherapy
16%
Erenumab
16%
Fremanezumab
16%
Eptinezumab
16%
Galcanezumab
16%
Atogepant
16%
Neuroscience
Clinical Guideline
100%
Migraine
100%
Monoclonal Antibody
12%
Angiotensin
12%
Fluoxetine
12%
Venlafaxine
12%
Amitriptyline
12%
Antiseizure Medication
12%
ACE Inhibitor
12%
Selective Serotonin Reuptake Inhibitor
12%
Tricyclic Antidepressant
12%
Headache
12%
Serotonin-Norepinephrine Reuptake Inhibitor
12%
Calcitonin Gene-Related Peptide Receptor Antagonist
12%
Lisinopril
12%
Topiramate
12%
Metoprolol
12%
Propranolol
12%
Telmisartan
12%
Candesartan
12%
Galcanezumab
12%
Eptinezumab
12%
Fremanezumab
12%
Erenumab
12%
Quality of Life
12%
Systematic Review
12%
Calcitonin Gene-Related Peptide
12%
Calcitonin Gene Related Peptide
12%